Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for 600 mg and 1200 mg oral solid extended-release guaifenesin combination products for the treatment of cough. This new drug represents the first prescription product in Adams’ current portfolio of respiratory products. [click link for full article]